{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:13:42Z","timestamp":1790626422512,"version":"4.1.0"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T00:00:00Z","timestamp":1612742400000},"content-version":"am","delay-in-days":373,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.metabol.2019.154049","type":"journal-article","created":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T17:48:07Z","timestamp":1576691287000},"page":"154049","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"special_numbering":"S","title":["Management of X-linked hypophosphatemia in adults"],"prefix":"10.1016","volume":"103","author":[{"given":"Anne-Lise","family":"Lecoq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Linglart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kamenick\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2019.154049_bb0005","doi-asserted-by":"crossref","unstructured":"A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat Genet 1995;11:130\u20136. doi:https:\/\/doi.org\/10.1038\/ng1095-130.","DOI":"10.1038\/ng1095-130"},{"key":"10.1016\/j.metabol.2019.154049_bb0010","doi-asserted-by":"crossref","first-page":"37419","DOI":"10.1074\/jbc.M304544200","article-title":"Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX","volume":"278","author":"Liu","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2019.154049_bb0015","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1359\/JBMR.0301264","article-title":"FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis","volume":"19","author":"Shimada","year":"2004","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"10.1016\/j.metabol.2019.154049_bb0020","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/jbmr.340","article-title":"A clinician\u2019s guide to X-linked hypophosphatemia","volume":"26","author":"Carpenter TO","year":"2011","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"10.1016\/j.metabol.2019.154049_bb0025","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1530\/EC-13-0103","article-title":"Therapeutic management of hypophosphatemic rickets from infancy to adulthood","volume":"3","author":"Linglart","year":"2014","journal-title":"Endocr Connect"},{"key":"10.1016\/j.metabol.2019.154049_bb0030","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1530\/EJE-15-0661","article-title":"Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms","volume":"174","author":"Che","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.metabol.2019.154049_bb0035","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S0002-9343(70)80032-8","article-title":"Parathyroid adenomas in chronic rickets","volume":"49","author":"Thomas","year":"1970","journal-title":"Am J Med"},{"key":"10.1016\/j.metabol.2019.154049_bb0040","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1001\/archpedi.1974.02110300114017","article-title":"Vitamin D-resistant rickets and parathyroid adenomas: renal transport of phosphate","volume":"128","author":"Talwalkar","year":"1974","journal-title":"Am J Dis Child 1960"},{"key":"10.1016\/j.metabol.2019.154049_bb0045","first-page":"39","article-title":"Hyperparathyroidism in patients with X-linked dominant hypophosphatemic rickets\u2013application of the calcium infusion test as an indicator for parathyroidectomy","volume":"5","author":"Alon","year":"1984","journal-title":"Int J Pediatr Nephrol"},{"key":"10.1016\/j.metabol.2019.154049_bb0050","first-page":"669","article-title":"Development of hypercalcemic hyperparathyroidism after long-term phosphate supplementation in hypophosphatemic osteomalacia","volume":"78","author":"Firth","year":"1985","journal-title":"Report of Two Cases Am J Med"},{"key":"10.1016\/j.metabol.2019.154049_bb0055","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/0002-9343(87)90711-X","article-title":"Hypercalcemic hyperparathyroidism complicating oncogenic osteomalacia. Effect of successful tumor resection on mineral homeostasis","volume":"83","author":"Reid","year":"1987","journal-title":"Am J Med"},{"key":"10.1016\/j.metabol.2019.154049_bb0060","first-page":"1514","article-title":"Tertiary hyperparathyroidism during high phosphate therapy of familial hypophosphatemic rickets","volume":"75","author":"Rivkees","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2019.154049_bb0065","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-2265.1995.tb01863.x","article-title":"Autonomous hyperparathyroidism in X-linked hypophosphataemia","volume":"42","author":"Knudtzon","year":"1995","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.metabol.2019.154049_bb0070","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/rheumatology\/35.6.598","article-title":"Tertiary hyperparathyroidism after long-term phosphate supplementation in adult-onset hypophosphataemic osteomalacia","volume":"35","author":"Narv\u00e1ez","year":"1996","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.metabol.2019.154049_bb0075","doi-asserted-by":"crossref","first-page":"468","DOI":"10.2169\/internalmedicine.39.468","article-title":"Tertiary hyperparathyroidism in X-linked hypophosphatemic rickets","volume":"39","author":"Wu","year":"2000","journal-title":"Intern Med Tokyo Jpn"},{"key":"10.1016\/j.metabol.2019.154049_bb0080","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/00008480-200108000-00015","article-title":"Ectopic cardiac calcification associated with hyperparathyroidism in a boy with hypophosphatemic rickets","volume":"13","author":"Moltz","year":"2001","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.metabol.2019.154049_bb0085","doi-asserted-by":"crossref","first-page":"5564","DOI":"10.1210\/jcem.86.11.7978","article-title":"Somatic mutations of the MEN1 gene and microsatellite instability in a case of tertiary hyperparathyroidism occurring during high phosphate therapy for acquired","volume":"86","author":"Sato","year":"2001","journal-title":"Hypophosphatemic Osteomalacia J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2019.154049_bb0090","first-page":"375","article-title":"Tertiary hyperparathyroidism after high-dose phosphate therapy in adult-onset hypophosphatemic osteomalacia. Endocr Pract Off J Am Coll Endocrinol Am Assoc","volume":"7","author":"Younis","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.metabol.2019.154049_bb0095","first-page":"127","article-title":"Evaluation of the parathyroid function in six patients with hypophosphatemic osteomalacia, including a case of tertiary hyperparathyroidism developing during combined oral phosphate and vitamin D therapy","volume":"60","author":"Jeon","year":"2003","journal-title":"Horm Res"},{"key":"10.1016\/j.metabol.2019.154049_bb0100","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1046\/j.1365-2265.2003.01685.x","article-title":"Prolonged high-dose phosphate treatment: a risk factor for tertiary hyperparathyroidism in X-linked hypophosphatemic rickets","volume":"58","author":"M\u00e4kitie","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.metabol.2019.154049_bb0105","doi-asserted-by":"crossref","unstructured":"Savio RM, Gosnell JE, Posen S, Reeve TS, Delbridge LW. Parathyroidectomy for tertiary hyperparathyroidism associated with X-linked dominant hypophosphatemic rickets. Arch Surg Chic Ill 1960 2004;139:218\u201322. doi:https:\/\/doi.org\/10.1001\/archsurg.139.2.218.","DOI":"10.1001\/archsurg.139.2.218"},{"key":"10.1016\/j.metabol.2019.154049_bb0110","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00467-004-1443-y","article-title":"The enigma of hyperparathyroidism in hypophosphatemic rickets","volume":"19","author":"Schmitt","year":"2004","journal-title":"Pediatr Nephrol Berl Ger"},{"issue":"Suppl. 1","key":"10.1016\/j.metabol.2019.154049_bb0115","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1530\/EJE-08-0383","article-title":"A case of X-linked hypophosphatemic rickets: complications and the therapeutic use of cinacalcet","volume":"159","author":"Raeder","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.metabol.2019.154049_bb0120","doi-asserted-by":"crossref","first-page":"274","DOI":"10.14310\/horm.2002.1277","article-title":"Cinacalcet in hyperparathyroidism secondary to X-linked hypophosphatemic rickets: case report and brief literature review","volume":"9","author":"Yavropoulou","year":"2010","journal-title":"Horm Athens Greece"},{"key":"10.1016\/j.metabol.2019.154049_bb0125","first-page":"266","article-title":"Tertiary hyperparathyroidism in a patient with X-linked hypophosphatemic rickets","volume":"11","author":"Tournis","year":"2011","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"10.1016\/j.metabol.2019.154049_bb0130","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1530\/EJE-15-0515","article-title":"Hereditary hypophosphatemia in Norway: a retrospective population-based study of genotypes, phenotypes, and treatment complications","volume":"174","author":"Rafaelsen","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.metabol.2019.154049_bb0135","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1530\/EJE-15-0595","article-title":"Serum PTH reference values established by an automated third-generation assay in vitamin D-replete subjects with normal renal function: consequences of diagnosing primary hyperparathyroidism and the classification of dialysis patients","volume":"174","author":"Souberbielle","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.metabol.2019.154049_bb0140","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0022-3476(72)80298-1","article-title":"Serum parathyroid hormone in hypophosphatemic vitamin D-resistant rickets","volume":"81","author":"Lewy","year":"1972","journal-title":"J Pediatr"},{"key":"10.1016\/j.metabol.2019.154049_bb0145","first-page":"1378","article-title":"Nocturnal hyperparathyroidism: a frequent feature of X-linked hypophosphatemia","volume":"78","author":"Carpenter","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2019.154049_bb0150","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s004670050669","article-title":"PHEX expression in parathyroid gland and parathyroid hormone dysregulation in X-linked hypophosphatemia","volume":"13","author":"Blydt-Hansen","year":"1999","journal-title":"Pediatr Nephrol Berl Ger"},{"key":"10.1016\/j.metabol.2019.154049_bb0155","first-page":"150","article-title":"Co-existence of X-linked hypophosphatemic rickets (XLH) and primary hyperparathyroidism: case report and review of the literature","volume":"5","author":"Tournis","year":"2005","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"10.1016\/j.metabol.2019.154049_bb0160","doi-asserted-by":"crossref","first-page":"E352","DOI":"10.1210\/jc.2010-0589","article-title":"Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment","volume":"95","author":"Carpenter","year":"2010","journal-title":"And Relationship to Parathyroid Status J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2019.154049_bb0165","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1681\/ASN.V11101865","article-title":"The in vitro effect of calcitriol on parathyroid cell proliferation and apoptosis","volume":"11","author":"Canalejo","year":"2000","journal-title":"J Am Soc Nephrol JASN"},{"key":"10.1016\/j.metabol.2019.154049_bb0170","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00467-002-1044-6","article-title":"Hypertension in hypophosphatemic rickets\u2013role of secondary hyperparathyroidism","volume":"18","author":"Alon","year":"2003","journal-title":"Pediatr Nephrol Berl Ger"},{"key":"10.1016\/j.metabol.2019.154049_bb0175","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1210\/jcem.82.8.4181","article-title":"Cardiovascular abnormalities in patients with X-linked hypophosphatemia","volume":"82","author":"Nehgme","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2019.154049_bb0180","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1507\/endocrj.EJ16-0199","article-title":"Hypertension is a characteristic complication of X-linked hypophosphatemia","volume":"64","author":"Nakamura","year":"2017","journal-title":"Endocr J"},{"key":"10.1016\/j.metabol.2019.154049_bb0185","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/0002-8703(84)90337-5","article-title":"Left ventricular function in patients with chronic hypophosphatemia","volume":"107","author":"Vered","year":"1984","journal-title":"Am Heart J"},{"key":"10.1016\/j.metabol.2019.154049_bb0190","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/jbmr.5650050508","article-title":"Normal left ventricular performance in children with X-linked hypophosphatemic rickets: a Doppler echocardiography study","volume":"5","author":"Vered","year":"1990","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"10.1016\/j.metabol.2019.154049_bb0195","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/07435800.2016.1242604","article-title":"Patients with FGF23-related hypophosphatemic rickets\/osteomalacia do not present with left ventricular hypertrophy","volume":"42","author":"Takashi","year":"2017","journal-title":"Endocr Res"},{"key":"10.1016\/j.metabol.2019.154049_bb0200","doi-asserted-by":"crossref","unstructured":"Gottdiener JS, Bednarz J, Devereux R, Gardin J, Klein A, Manning WJ, et al. American Society of Echocardiography recommendations for use of echocardiography in clinical trials. J Am Soc Echocardiogr Off Publ Am Soc Echocardiogr 2004;17:1086\u2013119. doi:10.1016\/j.echo.2004.07.013.","DOI":"10.1016\/j.echo.2004.07.013"},{"key":"10.1016\/j.metabol.2019.154049_bb0205","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0002-9149(02)02381-0","article-title":"Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy","volume":"90","author":"Grothues","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.metabol.2019.154049_bb0210","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1161\/CIRCIMAGING.111.966754","article-title":"Improved left ventricular mass quantification with partial voxel interpolation: in vivo and necropsy validation of a novel cardiac MRI segmentation algorithm","volume":"5","author":"Codella","year":"2012","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.metabol.2019.154049_bb0215","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2019.154049_bb0220","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/emmm.201303716","article-title":"FGF23 regulates renal sodium handling and blood pressure","volume":"6","author":"Andrukhova","year":"2014","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.metabol.2019.154049_bb0225","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cmet.2012.11.001","article-title":"Circulating fibroblast growth factors as metabolic regulators\u2013a critical appraisal","volume":"16","author":"Angelin","year":"2012","journal-title":"Cell Metab"},{"key":"10.1016\/j.metabol.2019.154049_bb0230","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1161\/ATVBAHA.110.214619","article-title":"Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals","volume":"31","author":"Mirza","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.metabol.2019.154049_bb0235","doi-asserted-by":"crossref","unstructured":"Xie W, M\u00e9chin M-C, Dubois SG, Lajeunesse D, van de Werve G. Up-regulation of liver glucose-6-phosphatase in x-linked hypophosphatemic mice. Horm Metab Res Horm Stoffwechselforschung Horm Metab 2002;34:288\u201392. doi:https:\/\/doi.org\/10.1055\/s-2002-33256.","DOI":"10.1055\/s-2002-33256"},{"key":"10.1016\/j.metabol.2019.154049_bb0240","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1210\/endo-118-1-441","article-title":"Increased metabolic rate in X-linked hypophosphatemic mice","volume":"118","author":"Vaughn","year":"1986","journal-title":"Endocrinology"},{"key":"10.1016\/j.metabol.2019.154049_bb0245","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1365-2265.2009.03558.x","article-title":"Correlation between plasma calcium, parathyroid hormone (PTH) and the metabolic syndrome (MetS) in a community-based cohort of men and women","volume":"71","author":"Ahlstr\u00f6m","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.metabol.2019.154049_bb0250","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1161\/CIRCULATIONAHA.108.808733","article-title":"Plasma parathyroid hormone and the risk of cardiovascular mortality in the community","volume":"119","author":"Hagstr\u00f6m","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2019.154049_bb0255","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1053\/meta.2000.17708","article-title":"Insulin sensitivity is inversely correlated with plasma intact parathyroid hormone level","volume":"49","author":"Chiu","year":"2000","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2019.154049_bb0260","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1007\/BF03345264","article-title":"Derangement of glucose metabolism in hyperparathyroidism","volume":"26","author":"Procopio","year":"2003","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.metabol.2019.154049_bb0265","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1530\/eje.1.02173","article-title":"Metabolic abnormalities in patients with normocalcemic hyperparathyroidism detected at a population-based screening","volume":"155","author":"Hagstr\u00f6m","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.metabol.2019.154049_bb0270","doi-asserted-by":"crossref","first-page":"R297","DOI":"10.1530\/EJE-17-0485","article-title":"Cardiovascular manifestations of primary hyperparathyroidism: a narrative review","volume":"177","author":"Pepe","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.metabol.2019.154049_bb0275","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1056\/NEJM198011273032203","article-title":"Hypophosphatemia and glucose intolerance: evidence for tissue insensitivity to insulin","volume":"303","author":"DeFronzo","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2019.154049_bb0280","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-2362.1993.tb00779.x","article-title":"On the relationships between mineral metabolism, obesity and fat distribution","volume":"23","author":"Lind","year":"1993","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.metabol.2019.154049_bb0285","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1055\/s-2007-978884","article-title":"Effects of hypophosphatemia on glucose tolerance and insulin secretion","volume":"30","author":"Paula","year":"1998","journal-title":"Horm Metab Res Horm Stoffwechselforschung Horm Metab"},{"key":"10.1016\/j.metabol.2019.154049_bb0290","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1053\/j.ajkd.2005.01.005","article-title":"Disturbances of phosphate metabolism: another feature of metabolic syndrome","volume":"45","author":"Kalaitzidis","year":"2005","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"key":"10.1016\/j.metabol.2019.154049_bb0295","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/sj.ejcn.1602375","article-title":"Association of serum phosphate levels with glucose tolerance, insulin sensitivity and insulin secretion in non-diabetic subjects","volume":"60","author":"Haap","year":"2006","journal-title":"Eur J Clin Nutr"},{"key":"10.1016\/j.metabol.2019.154049_bb0300","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.diabres.2008.08.018","article-title":"Serum phosphate levels and the risk of cardiovascular disease and metabolic syndrome: a double-edged sword","volume":"83","author":"Park","year":"2009","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.metabol.2019.154049_bb0305","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/ajcn\/79.5.820","article-title":"Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction","volume":"79","author":"Chiu","year":"2004","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.metabol.2019.154049_bb0310","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1210\/jc.2013-3577","article-title":"Blood vitamin D status and metabolic syndrome in the general adult population: a dose-response meta-analysis","volume":"99","author":"Ju","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2019.154049_bb0315","first-page":"879","article-title":"A prospective trial of phosphate and 1,25-dihydroxyvitamin D3 therapy in symptomatic adults with X-linked hypophosphatemic rickets","volume":"75","author":"Sullivan","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2019.154049_bb0320","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00223-009-9270-6","article-title":"Survey of the enthesopathy of X-linked hypophosphatemia and its characterization in Hyp mice","volume":"85","author":"Liang","year":"2009","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.metabol.2019.154049_bb0325","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1067\/mpd.2003.119","article-title":"Dental abnormalities in patients with familial hypophosphatemic vitamin D-resistant rickets: prevention by early treatment with 1-hydroxyvitamin D","volume":"142","author":"Chaussain-Miller","year":"2003","journal-title":"J Pediatr"},{"key":"10.1016\/j.metabol.2019.154049_bb0330","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1601-0825.2006.01326.x","article-title":"Dentin structure in familial hypophosphatemic rickets: benefits of vitamin D and phosphate treatment","volume":"13","author":"Chaussain-Miller","year":"2007","journal-title":"Oral Dis"},{"key":"10.1016\/j.metabol.2019.154049_bb0335","doi-asserted-by":"crossref","unstructured":"Haffner D, Emma F, Eastwood DM, Duplan MB, Bacchetta J, Schnabel D, et al. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol 2019. doi:https:\/\/doi.org\/10.1038\/s41581-019-0152-5.","DOI":"10.1038\/s41581-019-0152-5"},{"issue":"Suppl. 2","key":"10.1016\/j.metabol.2019.154049_bb0340","first-page":"367","article-title":"The changing face of hypophosphatemic disorders in the FGF-23 era","volume":"10","author":"Lee","year":"2013","journal-title":"Pediatr Endocrinol Rev PER"},{"key":"10.1016\/j.metabol.2019.154049_bb0345","doi-asserted-by":"crossref","first-page":"5358","DOI":"10.1210\/en.2005-0777","article-title":"Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice","volume":"146","author":"Perwad","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.metabol.2019.154049_bb0350","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1359\/jbmr.080417","article-title":"Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23","volume":"23","author":"Yamazaki","year":"2008","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"10.1016\/j.metabol.2019.154049_bb0355","doi-asserted-by":"crossref","unstructured":"Aono Y, Yamazaki Y, Yasutake J, Kawata T, Hasegawa H, Urakawa I, et al. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets\/osteomalacia. J Bone Miner Res Off J Am Soc Bone Miner Res 2009;24:1879\u201388. doi:https:\/\/doi.org\/10.1359\/jbmr.090509.","DOI":"10.1359\/jbmr.090509"},{"key":"10.1016\/j.metabol.2019.154049_bb0360","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/jbmr.275","article-title":"Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice","volume":"26","author":"Aono","year":"2011","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"10.1016\/j.metabol.2019.154049_bb0365","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1172\/JCI72829","article-title":"Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia","volume":"124","author":"Carpenter","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2019.154049_bb0370","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1210\/jc.2015-1551","article-title":"Prolonged correction of serum phosphorus in adults with X-linked hypophosphatemia using monthly doses of KRN23","volume":"100","author":"Imel","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2019.154049_bb0375","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.bonr.2016.05.004","article-title":"Effect of four monthly doses of a human monoclonal anti-FGF23 antibody (KRN23) on quality of life in X-linked hypophosphatemia","volume":"5","author":"Ruppe","year":"2016","journal-title":"Bone Rep"},{"key":"10.1016\/j.metabol.2019.154049_bb0380","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/jbmr.3475","article-title":"A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis: efficacy of burosumab in adults with XLH","volume":"33","author":"Insogna","year":"2018","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2019.154049_bb0385","doi-asserted-by":"crossref","unstructured":"Insogna KL, Rauch F, Kamenick\u00fd P, Ito N, Kubota T, Nakamura A, et al. Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X-Linked Hypophosphatemia: A Phase 3, Single-Arm, International Trial. J Bone Miner Res Off J Am Soc Bone Miner Res 2019. doi:https:\/\/doi.org\/10.1002\/jbmr.3843.","DOI":"10.1002\/jbmr.3843"},{"key":"10.1016\/j.metabol.2019.154049_bb0390","doi-asserted-by":"crossref","unstructured":"Carpenter TO, Whyte MP, Imel EA, Boot AM, H\u00f6gler W, Linglart A, et al. Burosumab Therapy in Children with X-Linked Hypophosphatemia. N Engl J Med 2018;378:1987\u201398. doi:https:\/\/doi.org\/10.1056\/NEJMoa1714641.","DOI":"10.1056\/NEJMoa1714641"},{"key":"10.1016\/j.metabol.2019.154049_bb0395","unstructured":"FDA available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761068s000lbl.pdf. Labels for BLA 761068 n.d."},{"key":"10.1016\/j.metabol.2019.154049_bb0400","unstructured":"EMA available at https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/crysvita-epar-product-information_en.pdf. EPAR-Product information n.d."},{"key":"10.1016\/j.metabol.2019.154049_bb0405","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/jbmr.1810","article-title":"Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets","volume":"28","author":"W\u00f6hrle","year":"2013","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"10.1016\/j.metabol.2019.154049_bb0410","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/jbmr.1738","article-title":"Hexa-D-arginine treatment increases 7B2\u00b7PC2 activity in hyp-mouse osteoblasts and rescues the HYP phenotype","volume":"28","author":"Yuan","year":"2013","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res"},{"key":"10.1016\/j.metabol.2019.154049_bb0415","first-page":"408","article-title":"Normal calcitonin stimulation of serum calcitriol in patients with X-linked hypophosphatemic rickets","volume":"75","author":"Econs","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2019.154049_bb0420","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1056\/NEJMc1010928","article-title":"Calcitonin administration in X-linked hypophosphatemia","volume":"364","author":"Liu","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2019.154049_bb0425","doi-asserted-by":"crossref","DOI":"10.1007\/s00223-017-0382-0","article-title":"Three-month randomized clinical trial of nasal calcitonin in adults with X-linked hypophosphatemia","author":"Sullivan","year":"2018","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.metabol.2019.154049_bb0430","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1172\/JCI81928","article-title":"CYP24 inhibition as a therapeutic target in FGF23-mediated renal phosphate wasting disorders","volume":"126","author":"Bai","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2019.154049_bb0435","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1210\/jc.2014-2017","article-title":"Effect of paricalcitol on circulating parathyroid hormone in X-linked hypophosphatemia: a randomized, double-blind, placebo-controlled study","volume":"99","author":"Carpenter","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2019.154049_bb0440","doi-asserted-by":"crossref","first-page":"7572","DOI":"10.4076\/1757-1626-2-7572","article-title":"The use of pre-operative imaging and intraoperative parathyroid hormone level to guide surgical management of tertiary hyperparathyroidism from X-linked hypophosphatemic rickets: a case report","volume":"2","author":"Neal","year":"2009","journal-title":"Cases J"},{"key":"10.1016\/j.metabol.2019.154049_bb0445","first-page":"193","article-title":"Tertiary hyperparathyroidism during the treatment of familial hypophosphatemic rickets","volume":"45","author":"Moreno Molina","year":"1996","journal-title":"An Esp Pediatr"},{"key":"10.1016\/j.metabol.2019.154049_bb0450","doi-asserted-by":"crossref","first-page":"658","DOI":"10.2215\/CJN.04981107","article-title":"Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets","volume":"3","author":"Alon","year":"2008","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"10.1016\/j.metabol.2019.154049_bb0455","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/00005792-198911000-00002","article-title":"X-linked hypophosphatemia: a clinical, biochemical, and histopathologic assessment of morbidity in adults","volume":"68","author":"Reid","year":"1989","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.metabol.2019.154049_bb0460","first-page":"541","article-title":"Low breast milk phosphorus concentration in familial hypophosphatemia","volume":"8","author":"Jonas","year":"1989","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.metabol.2019.154049_bb0465","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1007\/BF02405118","article-title":"Normal milk composition in lactating X-linked hypophosphatemic mice despite continued hypophosphatemia","volume":"35","author":"Delzer","year":"1983","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.metabol.2019.154049_bb0470","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00439-009-0631-z","article-title":"PHEX analysis in 118 pedigrees reveals new genetic clues in hypophosphatemic rickets","volume":"125","author":"Gaucher","year":"2009","journal-title":"Hum Genet"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049519302641?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049519302641?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:22:00Z","timestamp":1758428520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049519302641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":94,"alternative-id":["S0026049519302641"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2019.154049","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of X-linked hypophosphatemia in adults","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2019.154049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"154049"}}